Agenda item 2 Presentations Lucy Troup (LT), Clinical Neuroscientist • Overview of work being done on pain/chronic pain • Large body of scientific literature supporting the use of CBMP’s for pain: o Positive long term effects for pain, pain related symptoms and quality of life o Little evidence of increase to other harm related substances o Lack of human clinical trials/clinical data o Variations in regulatory models across countries potentially clouding evidence o Work around cannabis use disorder (CUD) and other health related issues • Moving forward for Scotland: o Existing research based in pre-clinical research o Difficulties in conducting clinical trials/significant barriers for scientists o Clinical outcome evaluations • Parallel problem spaces – physical pain vs harm from CBMP’s • Future work Rob Forbes (RF), Consultant Anaesthetist & Pain Specialist • Patients reporting significant benefits of using medicinal cannabis for pain • Barriers to prescribing: o Unfamiliar/stigma o Lack of Randomised Control Trials (RCT’s) o Restrictive guidance 2 o Fear of adverse effects • In America, teaching on medicinal cannabis has entered the undergraduate curriculum in approximately half of medical schools • Evidence of dependence shows rate of addiction is low, far lower than alcohol and other available medicines • Report for UK Parliament APPG for drug policy reform found good evidence of efficacy for cannabis and pain • Little evidence of cannabis as a ‘gateway drug’ Agenda item 3 Questions TW thanked the presenters for the interesting contributions and moved to questions: Anna Ross to AS – how do we get SIGN guidelines for cannabis based medicine for cancer pain and how can we get active engagement in the current development of guidelines i.e. patient involvement.